Impact of Reactive Oxygen Species on the Expression of Adhesion Molecules in Vivo
Many non-surgical tumor treatments induce reactive oxygen species (ROS) which result in cell damage. This study investigated the impact of ROS induction on the expression of adhesion molecules and whether α-tocopherol pre-treatment could have a protective effect. Experimental rat DS-sarcomas were treated with a combination of localized 44°C-hyperthermia, inspiratory hyperoxia and xanthine oxidase which together lead to a pronounced ROS induction. Further animals were pre-treated with α-tocopherol. The in vivoexpression of E- and N-cadherin, α-catenin, integrins αv, β3 and β5 as well as of the integrin dimer αvβ3 was assessed by flow cytometry. The expression of αv-, β3-integrin, of the αvβ3-integrin dimer and of E-cadherin was significantly reduced by the ROS-inducing treatment. This effect was partially reversible by α-tocopherol, indicating that ROS play a role in this process. N-cadherin, α-catenin and β5-integrin expression were unaffected by ROS. These results indicate that the expression of several adhesion molecules is markedly reduced by ROS and may result in a decrease in the structural stability of tumor tissue. Further studies are needed to clarify the impact of ROS induction on the metastatic behavior of tumors.
KeywordsXanthine Oxidase Circulate Tumor Cell Adhesion Molecule Expression Metastatic Behavior Outer Cell Membrane
Unable to display preview. Download preview PDF.
- 5.W.S. Wu. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 25, 695-705 (2006).Google Scholar
- 6.P. Workman, P. Twentyman, F. Balkwill, A. Balmain, D.J. Chaplin, J.A. Double, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edit.). Br. J. Cancer 77, 1-10 (1998).Google Scholar
- 14.D.G. McNeel, J. Eickhoff, F.T. Lee, D.M. King, D. Alberti, J.P. Thomas et al. Phase I trial of a monoclonal antibody specific for αvβ3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 11, 7851-7860 (2005).Google Scholar